Clinical trials: Pancreatic Diseases
Cystic Fibrosis
Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants
The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with…
- Trial name
- NCT07349394
- Testing
- VNZ/TEZ/D-IVA, Rosuvastatin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
Mannitol Dose Response Study in Cystic Fibrosis
Many cystic fibrosis patients die of lung failure caused by repeated lung infections from thick, sticky mucus. Past studies have shown Bronchitol inhalation may help to facilitate the clearance of mucus by altering its rheology…
- Trial name
- NCT00251056
- Testing
- mannitol
- Where
- 12 sites in Argentina, Canada
- Volunteers
- 48 people
- Sponsor
- Syntara
Cystic Fibrosis
Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis
This trial will consist of three arms: Part A, Part B, and Part C. Part A has two groups. The first group will enroll adult subjects with cystic fibrosis (CF) into a single ascending dose (SAD) treatment group.
- Trial name
- NCT02718495
- Testing
- PTI-428
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 56 people
- Sponsor
- Proteostasis Therapeutics, Inc.
Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas
Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
This clinical trial will evaluate the safety and tolerability of CRS 207 an investigational product that is a weakened form (attenuated) of Listeria monocytogenes, a type of bacteria that is commonly found in the environment.
- Conditions
- Malignant Epithelial Mesothelioma, Adenocarcinoma of the Pancreas, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of the Ovaries
- Trial name
- NCT00585845
- Testing
- CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
- Where
- 4 sites in United States, Israel
- Volunteers
- 17 people
- Sponsor
- Anza Therapeutics, Inc.
Metastatic Breast Cancer, Pancreatic Cancer
Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Capecitabine in Patients with Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic…
- Conditions
- Metastatic Breast Cancer, Pancreatic Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT02210364
- Testing
- lurbinectedin (PM01183), capecitabine
- Where
- 2 sites in Belgium, Spain
- Volunteers
- 81 people
- Sponsor
- PharmaMar
Cystic Fibrosis
Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease
The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of two dose levels of INS37217 (denufosol tetrasodium) Inhalation Solution in patients with cystic fibrosis (CF) lung disease.
- Trial name
- NCT00103714
- Testing
- denufosol tetrasodium (INS37217)
- Volunteers
- 72 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Cancer, Metastatic Cancer
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
- Trial name
- NCT04330664
- Testing
- MRTX849, TNO155
- Where
- 17 sites in United States
- Volunteers
- 86 people
- Sponsor
- Mirati Therapeutics Inc.
Cystic Fibrosis
Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients
A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of QR-010 in adults homozygous for ΔF508 Cystic Fibrosis.
- Trial name
- NCT02532764
- Testing
- QR-010
- Where
- 27 sites in United States, Belgium and 8 more
- Volunteers
- 70 people
- Sponsor
- ProQR Therapeutics
Cystic Fibrosis
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
The main objective of the study is to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug and to evaluate the safety of brensocatib compared to…
- Trial name
- NCT05090904
- Testing
- Brensocatib
- Where
- 14 sites in United States
- Volunteers
- 29 people
- Sponsor
- Insmed Incorporated
Gastric Cancer, Gastroesophageal Junction Cancer
Study for AZD4360 in Participants With Advanced Solid Tumours
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06921928
- Testing
- AZD4360
- Where
- 14 sites in United States, China and 3 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Type 1 Diabetes, Type 2 Diabetes
Closed Loop Glucose Control in a Simulated ICU Setting
This is a proof of concept safety study of a rule-based closed loop glucose control system designed for use in the intensive care unit setting.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Stress Induced Hyperglycemia
- Trial name
- NCT07646067
- Testing
- FUSION closed loop glucose control system
- Volunteers
- 6 people
- Sponsor
- Ideal Medical Technologies
Gastric Cancer, Pancreatic Cancer
Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers
A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers
- Trial name
- NCT04404595
- Testing
- CT041
- Where
- 16 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Cancer of Pancreas, Cancer of the Pancreas
Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint
This is a phase II, multi-center, open-label, single-arm clinical trial to be conducted in the United States. In approximately 55 centers, approximately 75 eligible locally advanced unresectable or metastatic pancreatic cancer…
- Conditions
- Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer, Pancreatic Cancer
- Trial name
- APPRISE 1 (NCT00613730)
- Testing
- Gemcitabine, panitumumab
- Volunteers
- 3 people
- Sponsor
- Amgen
Pancreatic Cancer
Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
This phase IB trial is studying how well giving gemcitabine together with Z650 works in treating patients with metastatic or recurrent pancreatic cancer.
- Trial name
- NCT04131192
- Testing
- Z650, Gemcitabine
- Where
- 2 sites in China
- Volunteers
- 13 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
T1DM - Type 1 Diabetes Mellitus, Pancreatogenic Diabetes Mellitus
An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events
This study is an open-label, single-arm, non-randomized trial designed to evaluate the safety and preliminary efficacy of CRG-002 administered via portal vein infusion or transplantation beneath the anterior rectus sheath in…
- Trial name
- NCT07503028
- Testing
- CRG002
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Celregen Therapeutics
Metastatic Pancreatic Cancer
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
This study is a multicenter, open-label, uncontrolled study to investigate the tolerability and safety of ONO-4578, ONO-4538, and standard of care in combination as first-line treatment in patients with metastatic pancreatic…
- Trial name
- NCT06538207
- Testing
- ONO-4578, ONO-4538, Oxaliplatin
- Where
- 9 sites in Japan
- Volunteers
- 46 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Neoplasms Pancreatic
Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer
Thermotherapy is a technology aiming at destroying tissue, for example tumor tissue. Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue…
- Trial name
- NCT02973217
- Testing
- Immunostimulating Interstitial Laser Thermotherapy
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Clinical Laserthermia Systems AB
Sarcoma, Carcinoma
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors
20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.
- Conditions
- Sarcoma, Carcinoma, Breast Cancer, Pancreatic Cancer
- Trial name
- NCT05860374
- Testing
- Recombinant oncolytic herpes simplex virus type 1 (R130)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Yunying Medical Technology
Pancreatic Adenocarcinoma, Ovarian Cancer
Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer
This Phase I/II trial evaluates LOAd703 in patients with cancer (pancreatic, biliary, colorectal or ovarian) together with their standard of care chemotherapy or using gemcitabine immune-conditioning.
- Conditions
- Pancreatic Adenocarcinoma, Ovarian Cancer, Biliary Carcinoma, Colorectal Cancer
- Trial name
- NCT03225989
- Testing
- LOAd703
- Where
- 2 sites in Sweden
- Volunteers
- 47 people
- Sponsor
- Lokon Pharma AB
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
- Conditions
- Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies
- Trial name
- NCT02231710
- Testing
- BPX-501 and Rimiducid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.